In this special Ask the Expert episode, we welcome Nuclear Medicine Specialist Dr Veronica Wong from Nepean Hospital and Telix Pharmaceuticals for an important and timely conversation about the ProstACT GLOBAL clinical trial and the future of targeted radiopharmaceutical therapy in prostate cancer.
As research continues to evolve, new therapies are emerging that aim to target prostate cancer cells more precisely than traditional treatments. One of these is TLX591, an investigational PSMA-targeted radio-antibody therapy currently being studied in the international ProstACT GLOBAL trial.
Hosted by global health moderator and cancer survivor Katie Clift, this session will explore what the ProstACT GLOBAL study involves, how TLX591 differs from existing treatments, and what this could mean for men with advanced prostate cancer. Dr Wong will also provide an update on current recruitment across 12 Telix Pharmaceutical trial sites in Australia and New Zealand, and explain what participation in a clinical trial involves.
For more information and support, please call 1800 22 00 99 or visit prostate.org.au.
HOST
Katie Clift
Director of International Public Relations Agency maybe, Global Moderator, Speaker & Breast Cancer Survivor
Katie Clift is Director of may:be, an international counter-cultural public relations agency. An MBA scholar of Warwick Business School. Katie has worked internationally on both sides of communications – in the media (radio, television & digital journalism) and as a PR, spokesperson, and corporate affairs executive - for both the private and public sectors. She has a decade of experience as a moderator, presenting sessions, interviews and press conferences globally, from the World Economic Forum in Davos to the Union for International Cancer Control’s World Cancer Congress and various in-person and online events. Katie was diagnosed with aggressive breast cancer in her 30s, and after 18 months of active treatment, returned to life and work more determined than ever to advocate for people affected by all types of cancer, and upscale communications for nonprofits globally.
EXPERT GUEST
Dr Veronica Wong, Nuclear Medicine Specialist, Nepean Hospital, Principal Investigator, ProstACT GLOBAL (ANZ Site)
Dr Veronica Wong is a Nuclear Medicine Specialist at Nepean Hospital with a clinical focus on genitourinary cancers, including prostate cancer. She is actively involved in clinical research and the delivery of innovative therapies through clinical trials. Dr Wong represents Telix Pharmaceuticals in her role as an investigator in the ProstACT GLOBAL study, contributing to the advancement of targeted radiopharmaceutical treatments for men with advanced prostate cancer. Her work combines evidence-based medicine with a strong commitment to patient-centered care, ensuring men and their families are supported with clear information when considering emerging treatment options.
